The rise in headwinds in the pharma industry due to inflation, increase in raw material costs, and excessive competition led to price erosion in the generic market. Although 2020-21 saw a skyrocketing of revenues and margins because of the Covid crisis, despite lockdowns and supply chain disruptions, Indian pharma companies are now having issues in maintaining their margins.
